Chairman and CEO of NRx Pharmaceutical

0


  • Conference begins on January 10, 2022

RADNOR, Pa., January 7, 2022 (GLOBE NEWSWIRE) – NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that its Chairman and CEO, Professor Jonathan Javitt, MD, MPH, will provide updates on the company’s activities at the HC Wainwright BioConnect virtual conference.

Details of the presentation are available below:

Date: Monday January 10, 2022

Time: 7:00 a.m. EST

Link to the presentation: https://journey.ct.events/view/1464b340-bd79-4a96-ae16-572a470d569b

About NRx Pharmaceuticals

NRx Pharmaceuticals (NRx) draws on more than 300 years of collective, scientific and drug development experience to improve patient health. The Company is developing the BriLife ™ Covid vaccine, developed by the Israel Biological Research Institute, under an exclusive license from the Israeli Ministry of Defense. NRx is further developing ZYESAMI® (aviptadil) for patients with COVID-19, and has received Fast Track designation by the United States Food and Drug Administration (FDA), and is currently in phase trials. 3 funded by the United States National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services, and the Medical Countermeasures Program, which is part of the United States Department of defense. The FDA has further granted a breakthrough therapy designation, a special protocol agreement, and a letter of biomarker support to NRx for NRX-101, an investigational drug to treat suicidal bipolar depression. NRX-101 is currently in phase 3 trials, with readings expected in 2022.

NRx is led by executives who have held leadership positions at Allergan, J&J, Lilly, Novartis, Pfizer and the US FDA. NRx is chaired by Professor Jonathan Javitt, MD, MPH, who has held leadership positions in six start-up biotech companies with public outings and has been appointed to advisory roles in four US presidential administrations. NRx’s board of directors includes Dr Sherry Glied, former Assistant Secretary of Health of the United States (ASPE), Daniel E. Troy, JD, former legal counsel to the US FDA, Chaim Hurvitz, former director of Teva and President of Teva International Group; and General HR McMaster, Ph.D. (US Army, Ret.) the 26th United States National Security Advisor.

Caution regarding forward-looking statements

This announcement by NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our outlook, product development, business outlook and market and industry trends and conditions, as well as company strategies, plans, objectives and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts and projections, as well as on assumptions made by the management of the Company and on information currently available to the latter.

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Therefore, you should not rely on any forward-looking statements, and all forward-looking statements are qualified herein by reference to the cautionary statements set forth above.

COMPANY CONTACT:
Jack Hirschfield – Head of Corporate Communications, NRx
jhirschfield@nrxpharma.com

RELATIONS WITH INVESTORS
Eric Goldstein
Managing Director – LifeSci Advisors
egoldstein@lifesciadvisors.com


Share.

Comments are closed.